Comparative Pharmacology
Head-to-head clinical analysis: PARAFLEX versus ROLVEDON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAFLEX versus ROLVEDON.
PARAFLEX vs ROLVEDON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
ROLVEDON (eflapegrastim) is a long-acting granulocyte colony-stimulating factor (G-CSF) agonist. It binds to G-CSF receptors on neutrophil progenitors, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
5 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Approximately 20 hours in adults; prolonged in renal impairment, requiring dose adjustment
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Primarily renal; approximately 80% of the dose excreted unchanged in urine, with minor biliary/fecal elimination (<10%)
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant